Slide 1: Investor Presentation
Medicure Inc. Investor Presentation August 25, 2022 MPH:TSXV
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-loo
Slide 3: Our Vision
WHERE WE ARE GOING Our Vision We want to be a leading cardiovascular pharmaceutical company in the U.S. We have a vertically integrated team, pipeline and acquisitions in place to build We want to be a leading provider of pharmaceutical growth. and healthcare products to U.S. customers We have a ver
Slide 4: What Sets Us Apart
What Sets Us Apart Our approach to engagement and service with healthcare professionals and patients Focusing on value for hospitals, prescribers, and patients 4 MPH:TSXV
Slide 5: Why Invest in Medicure Inc.
Why Invest in Medicure Inc. • Profitable and growing profit • Steady sales of Aggrastat • Zypitamag sales growing • Marley Drug – E-Commerce pharmacy • MC-1 – pediatric voucher upon completion of phase 3 trial of 10 PNPO patients • No Debt MPH:TSXV 5
Slide 6: Medicure's Acquisition of Marley Drug Pharmacy: The Industry Game-Changer
Medicure’s Acquisition of Marley Drug Pharmacy: The Industry Game-Changer Slides 25-28 MPH:TSXV 6
Slide 7: Our Products and Pipeline
Our Products and Pipeline DEVELOPMENT REGULATORY APPROVED PRODUCT CATEGORY / CLINICAL APPROVAL / MARKETED AGGRASTAT® Hospital IV Injectable Branded antiplatelet, grew from 2% to 65% market share Prescription ZYPITAMAG® Branded statin with large market potential Consumer Sodium Hospital IV Injectable
Slide 8: Strategic Approach
Strategic Approach 1 Maintain positive earnings and cash flow 3 Acquisitions of synergistic companies or through existing products and innovation in cardio products for US market direct-to-consumer sales PROFITABILIY DEVELOPMENT ACQUISITION 2 Expand product offering through development of high margi
Slide 9: Net Revenue Growth
Net Revenue Growth $40,000,000 Marley Drug $35,000,000 Apicore $30,000,000 Medicure $25,000,000 $20,000,000 $15,000,000 $10,000,000 $5,000,000 $0 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 MPH:TSXV
Slide 10: Key Financial Highlights
Key Financial Highlights Net Revenue Adjusted EBITDA Net Income (Loss) $8.0 $2.0 $10.0 $7.0 $1.5 *Forecast $5.0 $6.0 $1.0 $0.0 $5.0 $0.5 $CAD (M) -$5.0 $4.0 $0.0 -$10.0 $3.0 -$0.5 -$15.0 $2.0 -$1.0 $1.0 -$1.5 -$20.0 $0.0 -$2.0 -$25.0 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2019 2020 2021 2022 2020
Slide 11: Key Financial Highlights
Key Financial Highlights Capital Structure as of August 24, 2022 • Issued Shares 10,251,313 • Fully Diluted Total 10,977,313 • Share Price C$1.10 • Market Cap C$11.3M Financial Highlights • 2022 Q2 Net Revenue $5.7M vs $5.7M in Q1 • 2022 Q2 R&D Expenses $1.3M vs $0.3M in Q1 • 2022 Q2 Adj. EBITDA ($0
Slide 12: The Story
The Story medicure’
Slide 13: Medicure Leadership Team
Medicure Leadership Team Albert D. Friesen Neil Owens Reuben Saba Haaris Uddin Chief Executive Officer & President & Vice President, Chief Financial Officer Chairman of the Board Chief Operating Officer Scientific and Medical Affairs • Founded Medicure in • Joined Medicure in 2014 • Joined Medicure
Slide 14: Medicure's History and Trajectory
Medicure’s History and Trajectory 2024 Projected Launch of MC-1 NDA 2023 Projected Launch of Cardio ANDA 2022 Launch of Medicure’s E-Commerce Platform 2020 Acquisition of Marley Drug Pharmacy 2019 Acquisition of ZYPITAMAG, investment in Sensible Medical, launch of Sodium Nitroprusside, SIB returning
Slide 15: AGGRASTAT (tirofiban hydrochloride) Profile
AGGRASTAT® (tirofiban hydrochloride) Profile Estimated Patient Market Share Background: 100% (GP IIb/IIIa Inhibitors) • Hospital product (GP IIb/IIIa inhibitor) for acute cardiovascular care • US rights acquired in 2006 80% • High Dose Bolus (HDB) dosing approved in 2013 • New 15 mL bolus vial forma
Slide 16: AGGRASTAT Sales Update
AGGRASTAT Sales Update Aggrastat Net Revenue By Quarter Aggrastat Units Per Quarter Analysis ($ CAD Millions) 35,000 • Unit Demand in Q2 2022: $3.5 • 1% higher compared to Q1 2022 30,000 $3.0 • 4% lower compared to Q2 2021 25,000 $2.5 • Net Revenue in Q2 2022: 20,000 • 3% higher compared to Q1 2022
Slide 17: SAVI-PCI Study Met Its Primary Endpoint
SAVI-PCI Study Met Its Primary Endpoint Randomized clinical study evaluating AGGRASTAT (short and long infusions) compared to INTEGRILIN® (eptifibatide) These results fill a gap in clinical evidence and provide an exciting development to bolster the contemporary use of AGGRASTAT MPH:TSXV Please refe
Slide 18: Strategic Approach for AGGRASTAT
Strategic Approach for AGGRASTAT 1 Market use of LEVERAGE KOL AGGRASTAT through SUPPORT Key Opinion Leaders NEW CLINICAL 2 Market new clinical data from SAVI-PCI DATA MPH:TSXV 18
Slide 19: ZYPITAMAG (pitavastatin) Profile
ZYPITAMAG® (pitavastatin) Profile Key Information A New Type of Statin: • Lowers cholesterol, with some benefits over other statins • Metabolized differently from most other statins • Well tolerated with low rates of muscle pain 19 MPH:TSXV Please refer to IMPORTANT SAFETY INFORMATION on slide 35
Slide 20: ZYPITAMAG (pitavastatin) Profile
ZYPITAMAG® (pitavastatin) Profile Clinical Differentiation Target Patient Groups Zypitamag is different from most other statins (minimally Of 17 million Americans taking a statin, 5-10% have side effects processed by CYP enzymes) Direct competitor Livalo currently has 0.37% of the statin Reduced ris
Slide 21: ZYPITAMAG Sales Update
ZYPITAMAG Sales Update Zypitamag Net Revenue per Year Zypitamag Units Dispensed per Quarter* Analysis ($ CAD Thousands) • Units dispensed via Marley Drug and Marley Drug Copay Cards in Q2 2022: 450,000 $3,500 Copay Card • 25% higher compared to Q1 2022 400,000 $3,000 • 2.8x higher compared to Q2 202
Slide 22: Marketing Focus
Marketing Focus 1 Simplicity in pricing ACCESSIBILITY without need for insurance, filled via Marley Drug 2 Metabolized differently DIFFERENTIATE from other statins and well tolerated MPH:TSXV Please refer to IMPORTANT SAFETY INFORMATION on slide 35 22
Slide 23: Customer Quotes
Customer Quotes “The best lipid levels I “ZYPITAMAG just have had in treating works for me. And, it's cholesterol... I have affordable” not had any side effects” “I personally tried multiple statins and “With ZYPITAMAG - had intolerable side my cholesterol levels effects. Because are down and I ZYPI
Slide 24: Strategic Approach
Strategic Approach 1 We have a talented sales team meeting with SALES TEAM healthcare providers to share the benefits and accessibility of ZYPITAMAG 2 Market the benefits CONSUMER of ZYPITAMAG and MARKETING how it is different from other statins MPH:TSXV 24
Slide 25: Medicure Subsidiary - Marley Drug Pharmacy
Medicure Subsidiary - Marley Drug Pharmacy • A US pharmacy licensed to ship medications to all 50 states, Washington D.C. and Puerto Rico • Net Revenue in Q2 2022 of $1.78M, compared to $1.86M in Q1 2022 • Thousands of existing customers and proven success in marketing based on pricing of generic dr
Slide 26: Why Did Medicure Acquire Marley Drug
Why Did Medicure Acquire Marley Drug What this provides to Medicure 1. A more efficient distribution and marketing vehicle for ZYPITAMAG – a Branded drug 2. A marketing vehicle for other Branded drugs challenged to get insurance coverage 3. Saves on high fees to wholesalers and pharmacy benefit mana
Slide 27: Reasons Why Americans Pay Cash for Medications
Reasons Why Americans Pay Cash for Medications Factors Driving Americans to Pay Cash for Pharmaceuticals 1 2 3 4 5 High Not-Covered or Coverage Gap Deductibles Non-Preferred • Medicare Part D • More consumers are • High non-preferred ‘donut hole’ or enrolled in high co-pay coverage gap leads to dedu
Slide 28: E-Commerce Platform and Go Forward Plans
E-Commerce Platform and Go Forward Plans 1 Meet the demand of Americans who want to CONSUMER purchase medications online MARKETING with a seamless purchase experience 2 We are exploring BUSINESS opportunities that align DEVELOPMENT with our goals Marley Drug MPH:TSXV 28
Slide 29: Development of MC-1 for Rare Pediatric Disease
Development of MC-1 for Rare Pediatric Disease • PNPO deficiency is a rare pediatric disease, which leads to seizures and is fatal if untreated • The disease leads to the inability to produce a critical cofactor required for normal development • Currently there is orphan drug status, with no approve
Slide 30: New Products - Our Target Product Profile
New Products - Our Target Product Profile In-Hospital Growth Opportunity Products that can be licensed or Build on the experience, acquired with low or no initial relationships and success of investment, and if licensed can AGGRASTAT be acquired with set milestones Primary Care Branded Products for
Slide 31: Previous Investments and Returns to Shareholders
Previous Investments and Returns to Shareholders APICORE (2014-2017) SENSIBLE MEDICAL (2019) SIB (2019) • July 2014 – Acquired 5% interest in • USD $10M investment in Sensible • Completed substantial issuer bid (SIB) Apicore with a 3-year option to Medical, and still hold the investment in 2019 for
Slide 32: Key Takeaways About Medicure
5 Key Takeaways About Medicure 1. Medicure’s focus is on pharmaceuticals and healthcare products for the US market 2. Proven success with AGGRASTAT, building sales of ZYPITAMAG 3. Focus on direct consumer sales for growth and profitability through Marley Drug subsidiary 4. Pipeline of products inclu
Slide 33: Further Information
Further Information Visit our Websites Investor Relations Medicure.com ir@medicure.com AggrastatHDB.com 1.888.435.2220 (Ext. 228) Zypitamag.com Marleydrug.com Follow us Contact a Product Specialist Linkedin.com/company/medicure 1.800.509.0544 Twitter.com/MedicureInc Instagram.com/medicureinc MPH:TSX
Slide 34: Important Safety Information for AGGRASTAT (tirofiban hydrochloride) injection
Important Safety Information for AGGRASTAT (tirofiban hydrochloride) injection Indication: Aggrastat is indicated to reduce the rate of Warnings and Precautions: Aggrastat can cause serious thrombotic cardiovascular events (combined endpoint of bleeding. If bleeding cannot be controlled discontinue
Slide 35: Important Safety Information for ZYPITAMAG (pitavastatin) tablets
Important Safety Information for ZYPITAMAG (pitavastatin) tablets INDICATIONS & USAGE ZYPITAMAG is indicated as an adjunctive therapy to diet in adult patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), ap